European Innovation Council

Founded in 2012, Stablepharma specializes in developing processes for vaccine stabilization. Its flagship product, Stablevax, enables precise dosage pre-loading into syringes at manufacture, eliminating wastage. The company's technology platform converts existing vaccines and diagnostics into thermostable products, addressing global cold chain challenges.

AlzeCure Pharma is a Swedish pharmaceutical company dedicated to developing drug therapies targeting diseases affecting the central nervous system. Its primary focus lies in Alzheimer's disease, with five drug candidates at various stages of development.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden that focuses on developing innovative cell and gene therapies to treat cancer. The company’s portfolio includes four drug candidates: two oncolytic virus therapies, ELC-100 and ELC-201, and two CAR T-cell treatments, ELC-301 and ELC-401. Additionally, Elicera has developed a universal CAR T-cell technology platform named iTANK (ELC-001), designed to enhance the efficacy of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors. With its commitment to advancing immune-based cancer treatments, Elicera Therapeutics aims to improve outcomes for patients facing various forms of cancer.

Acorai develops a non-invasive heart failure monitoring platform centered around direct intracardiac pressure monitoring. Its patented technology combines sensor technologies and machine learning to enable accurate, cost-efficient care, reducing re-hospitalization and mortality rates.

Innoventric is an Israeli medical device company specializing in percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company's flagship product is the Trillium™ technology, designed to treat Tricuspid Valve Regurgitation through functional valve replacement using Cross-Caval anchoring and a unique multi-valve design.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Oryl Photonics specializes in developing laboratory instruments for pharmaceutical and biotech companies. Their core product provides a simple, reliable, and cost-effective method for measuring solubility, contributing to accelerated drug development and improved medicine. The company's unique technology preserves valuable substances during testing, offering a solubility measurement service that empowers researchers to make data-driven decisions and expedite product development.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

King's College London is a public research university in London, United Kingdom, and a constituent college of the University of London. Founded in 1829 by King George IV and the Duke of Wellington, it operates from multiple central London campuses and a campus in Denmark Hill, with a strong emphasis on medical and biomedical research and education. The institution supports a large community of students and staff and is known for its extensive graduate and postgraduate programmes. It is a founding member of the King's Health Partners academic health sciences centre and participates in major research and academic networks, including the Russell Group and Universities UK.

RS Research is a clinical-stage biotechnology company focused on developing nanomedicines for cancer treatment. Based in Istanbul, Turkey, it has developed a proprietary Sagitta drug-delivery platform that enables targeted chemotherapies across multiple indications. The company advances a portfolio of nanomedicine candidates through preclinical and clinical stages, with its lead program RS-0139 studied in Phase I oncology trials and supported by a GMP-certified production facility for clinical batch drug candidates. RS Research collaborates with international partners on co-development projects and offers ancillary services such as preclinical absorption, distribution, metabolism, and excretion testing, bioanalytical method development and validation, impurity and metabolite analysis, stability testing, toxicology studies, and patent-related due diligence and drafting support. The business aims to deliver targeted therapies with improved therapeutic indices through its nanocarrier technology and partnerships.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Acorai develops a non-invasive heart failure monitoring platform centered around direct intracardiac pressure monitoring. Its patented technology combines sensor technologies and machine learning to enable accurate, cost-efficient care, reducing re-hospitalization and mortality rates.

Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

RUBYnanomed provides non-invasive monitoring of cancer progression. They enable the analysis of their phenotypic, genetic, and functional characteristics, facilitating unprecedentedly frequent monitoring of cancer progression in a minimally invasive, cost-efficient way. They enable oncologists to detect and analyze the evolution of cancer subtypes and therapeutic resistance mechanisms in each patient, providing personalized therapy insights to treat their patients.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

ADmit Therapeutics is a biotechnology company that develops diagnostic tests for early detection of Alzheimer’s disease. Its blood-based assay uses epigenetic analysis to assess mitochondrial DNA methylation, including methylcytosines, through next-generation sequencing, and does not rely on beta-amyloid or tau markers. The test is intended to aid pharmaceutical research by enabling early diagnosis and streamlined drug development. The company was founded in 2017 and is based in Begues, Spain.

Carthera is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices for treating brain disorders. Its proprietary device, SonoCloud®, is an intracranial ultrasound implant that, when used in conjunction with an intravenous microbubble agent, temporarily opens the blood-brain barrier. This mechanism significantly enhances the delivery of therapeutic molecules to the brain, potentially providing new treatment options for debilitating neurological conditions. Through its technology, Carthera aims to enable healthcare professionals to address challenging brain disorders more effectively.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

Founded in 2019, Arthex Biotech is a Spanish biotechnology company specializing in the development of antisense RNA therapies for genetic diseases. The company, spun off from the University of Valencia, leverages its team's expertise in drug discovery and microRNAs to create innovative treatments.

Smart Immune is a clinical‑stage biotechnology company developing next‑generation hematopoietic stem cell–based biotherapies to improve outcomes for patients with severe diseases. Its flagship program uses T‑cell progenitors (ProTcells) to enable rapid, polyclonal, and safe immune reconstitution after transplantation. The platform integrates targeted conditioning, gene therapy, and genome editing to extend treatment options for inherited blood disorders, blood cancers, and other life‑threatening conditions.

Smart Immune is a clinical‑stage biotechnology company developing next‑generation hematopoietic stem cell–based biotherapies to improve outcomes for patients with severe diseases. Its flagship program uses T‑cell progenitors (ProTcells) to enable rapid, polyclonal, and safe immune reconstitution after transplantation. The platform integrates targeted conditioning, gene therapy, and genome editing to extend treatment options for inherited blood disorders, blood cancers, and other life‑threatening conditions.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

iLoF develops an AI-powered digital health platform that accelerates personalized drug discovery. It uses advanced photonics to collect data, building a digital library of biomarkers for studying tailored treatments and making clinical trials more efficient.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

iThera Medical develops biomedical imaging technology based on photonic molecular imaging and multispectral optoacoustic tomography (MSOT) for preclinical and clinical applications. The company leverages the photoacoustic effect to visualize and quantify anatomical, functional, and molecular information in vivo, including deep tissue visualization and real-time imaging, enabling non-invasive assessment of tumors and inflammatory diseases. Founded in 2010 as a spin-off from Helmholtz Zentrum München, iThera Medical focuses on advancing MSOT technology for use in preclinical research and clinical trials, supporting researchers and clinicians in obtaining deeper insights into biological processes without invasive procedures.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Founded in 2018, Resistell develops and markets a diagnostic device for phenotypic antibiotic susceptibility testing. Its unique method detects movement caused by living bacterial cells to determine bacterial resistance to antibiotics.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Protinhi Therapeutics is a preclinical stage biotechnology company focused on the development of antiviral drugs aimed at combating various viral threats, including dengue, Zika, and COVID-19. The company utilizes proprietary technology and compounds to create therapies that inhibit viral proteases, effectively preventing the viruses from replicating. This mechanism allows healthcare providers to better control the spread of these diseases, addressing significant public health challenges.

Xenikos develops innovative immunotherapy medicines using anti-T-cell antibodies. These therapies aim to reset patients' immune systems quickly and efficiently, targeting activated adult T cells to improve treatment outcomes for serious immune diseases.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Herantis Pharma is a biotech company focused on addressing unmet clinical needs, particularly in the field of neurodegenerative diseases. The company's primary development program centers on HER-096, a peptidomimetic molecule designed to mimic the biological activity of the neuroprotective CDNF protein. By targeting Parkinson's disease, Herantis Pharma aims to develop disease-modifying therapies that could significantly improve patient outcomes.

Herantis Pharma is a biotech company focused on addressing unmet clinical needs, particularly in the field of neurodegenerative diseases. The company's primary development program centers on HER-096, a peptidomimetic molecule designed to mimic the biological activity of the neuroprotective CDNF protein. By targeting Parkinson's disease, Herantis Pharma aims to develop disease-modifying therapies that could significantly improve patient outcomes.

Akknatek is an ophthalmology technology company developing postoperative monitoring and treatment solutions for intraocular lenses (IOLs). Its patented lens reviewer aids clinicians in deciding how to manage dislocated IOLs, with the aim of reducing post-operative refractive complications after cataract surgery and lowering the need for additional refractive procedures. The technology is designed to simplify postoperative management and support improved visual outcomes for patients undergoing cataract surgery.

VIVAN Therapeutics pioneers personalized cancer therapeutics using innovative assay technology. It licenses technology from the Center for Personalized Cancer Therapeutics at Mount Sinai New York, offering a comprehensive, genomics-based drug screening service enabled by blockchain. The company's approach intelligently designs personalized treatments, combining cancer and non-cancer drugs to reduce toxicity and cost.

Vigor Medical Technologies Ltd. develops innovative devices for treating chest trauma and managing thoracic/abdominal drainage. Its self-fixation sealing devices prevent lung and heart collapse, reducing fatality rates associated with chest trauma, which affects over 4 million people worldwide annually.

Cherry Biotech is a biomedical technology company that develops Organ on Chip instruments and microfluidic systems to culture and mimic human organs under physio-pathological conditions for drug discovery and personalized medicine. The company also offers temperature controllers for rapid temperature shifts and next-generation 3D cell culture technologies to recreate the human cell microenvironment, supporting drug development and toxicity assessment.

Founded in 2019, Arthex Biotech is a Spanish biotechnology company specializing in the development of antisense RNA therapies for genetic diseases. The company, spun off from the University of Valencia, leverages its team's expertise in drug discovery and microRNAs to create innovative treatments.

Founded in 2019, Arthex Biotech is a Spanish biotechnology company specializing in the development of antisense RNA therapies for genetic diseases. The company, spun off from the University of Valencia, leverages its team's expertise in drug discovery and microRNAs to create innovative treatments.

Founded in 2015, ATXA Therapeutics is an Irish pharmaceutical company dedicated to developing novel small molecule drugs for treating pulmonary arterial hypertension (PAH). With a strong scientific foundation and over €15 million in grant funding, the company focuses on advancing clinical trials and securing marketing authorization for its therapies.

Founded in 2015, ATXA Therapeutics is an Irish pharmaceutical company dedicated to developing novel small molecule drugs for treating pulmonary arterial hypertension (PAH). With a strong scientific foundation and over €15 million in grant funding, the company focuses on advancing clinical trials and securing marketing authorization for its therapies.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Immunethep is a biotechnology company focused on developing bacterial immunotherapies for immune system related diseases. It originated as a spin-off from the University of Porto, using proprietary technology to counter bacteria that suppress the host immune response. The company targets a shared virulence mechanism used by diverse bacteria responsible for life-threatening infections, aiming to create broad-spectrum immunotherapies and innovative neonatal vaccines to protect newborns from bacterial infections. Through its pipeline, Immunethep seeks to enable patients to mount effective immunity and reduce the burden of multi-bacterial diseases with advanced therapeutic strategies.

Immunethep is a biotechnology company focused on developing bacterial immunotherapies for immune system related diseases. It originated as a spin-off from the University of Porto, using proprietary technology to counter bacteria that suppress the host immune response. The company targets a shared virulence mechanism used by diverse bacteria responsible for life-threatening infections, aiming to create broad-spectrum immunotherapies and innovative neonatal vaccines to protect newborns from bacterial infections. Through its pipeline, Immunethep seeks to enable patients to mount effective immunity and reduce the burden of multi-bacterial diseases with advanced therapeutic strategies.

Nanordica Medical is an Estonian medical technology company that develops wound care solutions based on patented nanotechnology, combining copper and silver in nanofibers to remove infection and support healing in chronic wounds. The company has launched a veterinary wound dressing and is developing a first-in-class human dressing for hard-to-heal wounds such as diabetic foot ulcers. Clinical data suggest superior efficacy of the Nanordica dressing compared with conventional silver-based dressings. The underlying technology uses silver nanoparticles blended with other components to broaden antibacterial activity, including against drug-resistant strains.

Akknatek is an ophthalmology technology company developing postoperative monitoring and treatment solutions for intraocular lenses (IOLs). Its patented lens reviewer aids clinicians in deciding how to manage dislocated IOLs, with the aim of reducing post-operative refractive complications after cataract surgery and lowering the need for additional refractive procedures. The technology is designed to simplify postoperative management and support improved visual outcomes for patients undergoing cataract surgery.

Protinhi Therapeutics is a preclinical stage biotechnology company focused on the development of antiviral drugs aimed at combating various viral threats, including dengue, Zika, and COVID-19. The company utilizes proprietary technology and compounds to create therapies that inhibit viral proteases, effectively preventing the viruses from replicating. This mechanism allows healthcare providers to better control the spread of these diseases, addressing significant public health challenges.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

Kahun is a healthcare technology company that offers an online medical platform designed to assist physicians in making informed clinical decisions. By cataloging clinical information from peer-reviewed medical literature, Kahun's platform employs artificial intelligence diagnostic engines to extract relevant insights. This approach not only streamlines the clinical intake process but also enhances the transparency and explainability of healthcare decisions. By optimizing physicians' documentation time and overall cognitive load, Kahun aims to improve clinical outcomes and facilitate faster, evidence-based decision-making within healthcare organizations.

Restore Medical develops a device-based therapy for congestive heart failure. Its product, ContraBand, is a catheter-delivered implant in the pulmonary arteries designed to improve patient quality of life and reduce hospital readmission rates.

Ovagen is a biotechnology company specializing in the commercial production of germ-free chicken eggs and birds. Primarily serving the pharmaceutical industry, Ovagen offers contract research services and expertise in specific poultry and rodent research technologies to Good Manufacturing Practice (GMP) standards.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

PhosPrint, established in 2019 and headquartered in Agia Paraskevi, Attiki, specializes in laser bioprinting systems and regenerative medicine. The company's core business involves developing and providing on-site cell printing during surgeries, aiming to facilitate tissue regeneration and advance medical research. PhosPrint's offerings include healthcare technology products that leverage laser bioprinting and biotechnology research, enabling researchers and medical professionals to access innovative tools and procedures to combat diseases and medical conditions.

Synergia Medical is a Belgium-based medical device company developing neurostimulation technologies. It advances an optoelectronic neurostimulator platform that integrates biomaterials, optical components, biosensors and microelectronics to enable implantable and potentially MRI-safe devices. The focus is on MRI-safe, implanted neurostimulators for drug-resistant epilepsy and other indications, with wires replaced by fiber optics and photovoltaic cells that convert light into electrical impulses. Founded in 2013 and headquartered in Mont-Saint-Guibert, the company pursues next-generation neurostimulation solutions, including its NAOS platform, and has pursued ISO13485 certification. Development is supported by private investors and public research grants, reflecting a multidisciplinary approach to bring novel neurostimulation devices to market.

AuriGen Medical Limited is an innovative company based in Dublin, Ireland, specializing in electrophysiology and structural heart solutions. Founded in 2016, AuriGen develops advanced left atrial appendage (LAA) implants aimed at addressing the stroke and arrhythmia risks associated with persistent atrial fibrillation (AF). The company targets a significant and growing patient population, particularly those with medication-resistant AF, which affects over three million individuals across the United States and Europe. AuriGen's technology offers a novel trans-septal implant that not only treats AF effectively but also reduces the reliance on anticoagulants and anti-arrhythmic medications. By providing cost-effective treatment options, AuriGen aims to improve patient outcomes while addressing the rising financial burden of managing chronic cardiac conditions in aging populations.

Qubit Pharmaceuticals is a Paris-based drug discovery company established in 2020. It develops a simulation platform that reduces the cost and duration of preclinical development by using proprietary force field models and molecular dynamics to perform virtual screening and visualization, enabling the identification of viable drug candidates. The platform applies quantum physics-inspired modeling to support biopharmaceutical research and aims to translate advanced computational methods into practical tools for drug development.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden that focuses on developing innovative cell and gene therapies to treat cancer. The company’s portfolio includes four drug candidates: two oncolytic virus therapies, ELC-100 and ELC-201, and two CAR T-cell treatments, ELC-301 and ELC-401. Additionally, Elicera has developed a universal CAR T-cell technology platform named iTANK (ELC-001), designed to enhance the efficacy of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors. With its commitment to advancing immune-based cancer treatments, Elicera Therapeutics aims to improve outcomes for patients facing various forms of cancer.

Neurosoft Bioelectronics specializes in developing soft, implantable electrodes designed to interface with nervous tissues. Their flagship product, SOFT ECoG, is a subdural electrode used for recording and stimulating the brain's surface, offering improved recordings, reduced current speed, minimized MRI artifacts, enhanced bio-integration, and precise anatomical targeting.

Legacy Healthcare is a biotechnology company developing safer drugs for autoimmune and inflammatory diseases, including therapies targeting moderate to severe alopecia areata. It focuses on treating chronic conditions in a manner safer for use, particularly in fragile populations such as children, cancer patients, and the elderly who may be on multiple medications, with the aim of improving quality of life.

Nuclidium develops novel radiopharmaceutical tracers for cancer diagnostics. Its platform aims to detect specific target molecules on tumors, enabling more accurate staging and personalized treatment options.

Piomic Medical develops a non-invasive, portable handheld device to treat chronic wounds, particularly hard-to-heal leg and foot ulcers. The COMS One Therapy System combines optical and magnetic stimulation to promote wound healing, with clinical data indicating safe use, accelerated wound closure, reduced pain, and improved quality of life. The device is lightweight and user-friendly, designed for use in clinics, ambulatory settings, and home care, enabling patients to continue treatment outside traditional facilities. By offering a safe and effective non-invasive therapy, Piomic Medical aims to alleviate the burden of chronic wounds on patients and healthcare systems.

Ovagen is a biotechnology company specializing in the commercial production of germ-free chicken eggs and birds. Primarily serving the pharmaceutical industry, Ovagen offers contract research services and expertise in specific poultry and rodent research technologies to Good Manufacturing Practice (GMP) standards.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

NeuroKaire develops personalized psychiatry testing tools. It uses innovative technology to predict the most effective drug treatment for patients, enabling faster recovery, fewer side effects, and lower dosing.

BrainEver is a medical research company focused on developing innovative drugs for neurodegenerative disorders. Building on research by Alain Prochiantz and his team, BrainEver investigates the role of homeoproteins, which are essential for brain development and ongoing neuronal functions. The company hypothesizes that administering homeoproteins can enhance the physiological resilience of neurons and improve clinical symptoms in patients. Among its drug candidates, Engrailed 1 (BREN01) is the most advanced, aimed at treating Parkinson Disease and Amyotrophic Lateral Sclerosis (ALS). Additionally, BrainEver is actively developing a pipeline of four more drug candidates targeting other neurodegenerative conditions, including Huntington Disease and Optic Neuropathies. Through its research and development efforts, BrainEver seeks to provide effective therapeutic options for healthcare practitioners and their patients.

InVera Medical specializes in developing innovative medical devices focused on treating chronic venous disease. Their flagship product, BioVena™, offers a less invasive, pain-free solution for varicose veins and venous ulcers, utilizing the body's natural biological response.

Betalin Therapeutics is a privately-held company dedicated to developing innovative cell therapy solutions for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. This platform combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. The EMP aims to offer an alternative to traditional insulin therapy, potentially eliminating the need for insulin injections and glucose monitoring in patients. Following promising in-vitro and preliminary in-vivo results, Betalin Therapeutics is focused on optimizing the therapy using animal models and preparing to submit an Investigational New Drug (IND) application to the FDA in anticipation of advancing to clinical trials.

Yonalink operates a global network comprising over 30,000 medical centers. It specializes in real-time collection of clinical trial data through its platform, which streamlines electronic health records (EHR) to electronic data capture (EDC), employs AI-driven case report form (CRF) data mapping, and facilitates secure, automated migration of research data from health records. This service enhances trial efficiency, improves data quality, reduces staff burnout at medical centers, and expands access to novel patient care opportunities. Additionally, the platform enables management of clinical trial operations and vendors, accelerates drug and device development, promotes patient diversity and enrollment, and ensures secure, fast, and error-free data capture processes for healthcare providers and researchers.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Filterlex Medical is a medical device company focused on cardiovascular embolic protection. It develops embolic protection devices to reduce the risk of stroke and other embolic complications during catheter-based structural heart procedures, including transcatheter aortic valve implantation. Its CAPTIS full-body embolic protection device is designed for intuitive deployment and retrieval and is compatible with multiple catheter sizes, enabling integration into existing workflows. The company aims to improve patient safety during minimally invasive heart valve replacement procedures. It was founded in 2015 and is based in Yokneam, Israel.

VBL Therapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel treatments for cancer and immune-inflammatory diseases. The company utilizes two proprietary platform technologies that harness the body's natural physiological and genetic regulatory elements. Its lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, specifically recurrent glioblastoma, an aggressive form of brain cancer. In addition to its oncology efforts, VBL Therapeutics is pursuing programs that target anti-inflammatory diseases, leveraging its Lecinoxoid platform technology. The company's diverse portfolio reflects its commitment to advancing innovative therapeutic solutions in the biopharmaceutical landscape.

VBL Therapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel treatments for cancer and immune-inflammatory diseases. The company utilizes two proprietary platform technologies that harness the body's natural physiological and genetic regulatory elements. Its lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, specifically recurrent glioblastoma, an aggressive form of brain cancer. In addition to its oncology efforts, VBL Therapeutics is pursuing programs that target anti-inflammatory diseases, leveraging its Lecinoxoid platform technology. The company's diverse portfolio reflects its commitment to advancing innovative therapeutic solutions in the biopharmaceutical landscape.

Criam is a Portuguese biotechnology company based in Braga that develops portable diagnostic technology for blood typing and infectious disease detection. Its stand-alone platform does not require electricity or laboratory infrastructure, enabling rapid testing at the point of care. A single reader can perform multiple tests using cartridges and computer vision algorithms to detect a broad range of diseases, including HIV, with real-time data to support clinical decisions. The system leverages lab-on-a-chip concepts and biomarker detection algorithms to deliver fast, user-friendly, and cost-effective diagnostics in diverse settings, including remote environments and emergency care.

Innoventric is an Israeli medical device company specializing in percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company's flagship product is the Trillium™ technology, designed to treat Tricuspid Valve Regurgitation through functional valve replacement using Cross-Caval anchoring and a unique multi-valve design.

Healium Medical develops a contactless ultrasound ablation system for atrial fibrillation that enables circumferential pulmonary vein isolation with real-time lesion monitoring. The system uses an over-the-wire catheter with a proprietary ultrasound transducer positioned at the pulmonary vein ostium to deliver rapid, non-contact ablation and provide immediate feedback on lesion formation. The solution aims to simplify the procedure, shorten procedure time, and improve efficacy compared with traditional tissue-contact approaches. Founded in 2017, the company is headquartered in Yokneam Illit, Israel.

Healium Medical develops a contactless ultrasound ablation system for atrial fibrillation that enables circumferential pulmonary vein isolation with real-time lesion monitoring. The system uses an over-the-wire catheter with a proprietary ultrasound transducer positioned at the pulmonary vein ostium to deliver rapid, non-contact ablation and provide immediate feedback on lesion formation. The solution aims to simplify the procedure, shorten procedure time, and improve efficacy compared with traditional tissue-contact approaches. Founded in 2017, the company is headquartered in Yokneam Illit, Israel.

iThera Medical develops biomedical imaging technology based on photonic molecular imaging and multispectral optoacoustic tomography (MSOT) for preclinical and clinical applications. The company leverages the photoacoustic effect to visualize and quantify anatomical, functional, and molecular information in vivo, including deep tissue visualization and real-time imaging, enabling non-invasive assessment of tumors and inflammatory diseases. Founded in 2010 as a spin-off from Helmholtz Zentrum München, iThera Medical focuses on advancing MSOT technology for use in preclinical research and clinical trials, supporting researchers and clinicians in obtaining deeper insights into biological processes without invasive procedures.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

iThera Medical develops biomedical imaging technology based on photonic molecular imaging and multispectral optoacoustic tomography (MSOT) for preclinical and clinical applications. The company leverages the photoacoustic effect to visualize and quantify anatomical, functional, and molecular information in vivo, including deep tissue visualization and real-time imaging, enabling non-invasive assessment of tumors and inflammatory diseases. Founded in 2010 as a spin-off from Helmholtz Zentrum München, iThera Medical focuses on advancing MSOT technology for use in preclinical research and clinical trials, supporting researchers and clinicians in obtaining deeper insights into biological processes without invasive procedures.

Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Amadix develops cancer diagnostics with a focus on non-invasive screening and early detection. It aims to detect tumors years before symptoms and provide screening signatures in blood to address unmet needs in oncology. Its most advanced product, Colofast, is a blood-based signature for colorectal cancer and advanced adenoma screening, designed to reduce mortality from colon cancer by enabling early intervention. The company pursues analytical validation and demonstration of clinical validity and utility through international multicentre studies, with plans for worldwide commercialization. The leadership combines experience in oncology diagnostics, pharmaceuticals, biotechnology, and intellectual property, and independent board members provide guidance on strategy, commercialization, and business development in Europe and the US.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Yonalink operates a global network comprising over 30,000 medical centers. It specializes in real-time collection of clinical trial data through its platform, which streamlines electronic health records (EHR) to electronic data capture (EDC), employs AI-driven case report form (CRF) data mapping, and facilitates secure, automated migration of research data from health records. This service enhances trial efficiency, improves data quality, reduces staff burnout at medical centers, and expands access to novel patient care opportunities. Additionally, the platform enables management of clinical trial operations and vendors, accelerates drug and device development, promotes patient diversity and enrollment, and ensures secure, fast, and error-free data capture processes for healthcare providers and researchers.

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company focused on inflammatory disorders by strengthening epithelial barrier integrity, a key factor in the progression of diseases affecting the skin, lungs, intestinal tract, and genital tract. It develops proprietary, orally available macrolide drug candidates with potential as first-in-class, disease-modifying therapies for chronic respiratory diseases and other significant unmet medical needs. Its lead candidate, EP395, aims to be the first oral, non-antibiotic macrolide that reinforces barrier function and provides anti-inflammatory effects for COPD and related inflammatory airway conditions.

RemedyBio is an Irish biotechnology company specializing in immunology-focused drug discovery and development. It has pioneered innovative approaches to understanding the immune system and identifying new therapies.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, that specializes in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures, primarily in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, designed to effectively close large arteriotomies resulting from transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Founded in 2008, Vivasure Medical is committed to advancing techniques that enhance patient outcomes in vascular access procedures.

PROSION Therapeutics is a biotechnology company developing innovative drugs to address previously undruggable targets linked to various hard-to-treat diseases, including cancer, diabetes, Alzheimer's, and cardiovascular diseases.

RUBYnanomed provides non-invasive monitoring of cancer progression. They enable the analysis of their phenotypic, genetic, and functional characteristics, facilitating unprecedentedly frequent monitoring of cancer progression in a minimally invasive, cost-efficient way. They enable oncologists to detect and analyze the evolution of cancer subtypes and therapeutic resistance mechanisms in each patient, providing personalized therapy insights to treat their patients.

Qubit Pharmaceuticals is a Paris-based drug discovery company established in 2020. It develops a simulation platform that reduces the cost and duration of preclinical development by using proprietary force field models and molecular dynamics to perform virtual screening and visualization, enabling the identification of viable drug candidates. The platform applies quantum physics-inspired modeling to support biopharmaceutical research and aims to translate advanced computational methods into practical tools for drug development.

Glycanostics is a start-up focused on developing innovative cancer diagnostic tests, specifically targeting prostate cancer. The company specializes in creating clinically validated and registered non-invasive liquid biopsy tests that analyze glycan changes on proteins, such as prostate-specific antigen (PSA). This technology aims to deliver accurate and affordable diagnostic solutions, assisting healthcare professionals in making informed decisions regarding the necessity of biopsies and monitoring patients post-biopsy. Through its advancements in cancer diagnostics, Glycanostics seeks to improve early detection and patient outcomes.